Trials / Unknown
UnknownNCT04586361
Prospective Analysis of Introperative RegenLab PRP and Hyaluronic Acid in Patients With Knee ACL Tear
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Kaohsiung Veterans General Hospital. · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
Purpose: The purpose of this article is to examine the clinical application of PRP and PRP+hyaluronic acid in disorders in the knee. Methods: The study was conducted on 150 adult patients with age over 20 years old affected by unilateral ACL complete tear and receiving ACL reconstruction. We divided the patients in three groups, and we treated the group A with perioperative injection of HHA, group B with perioperative HHA+PRP, group C with perioperative normal saline. Follow-up: Every 1,3,and 12months, we recheck physical exmianation at OPD and recheck MRI at postoperative 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | RegenLab PRP | PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit. |
| COMBINATION_PRODUCT | hyaluronic acid | Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life. |
| OTHER | normal saline | In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient. |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2021-09-15
- Completion
- 2022-09-15
- First posted
- 2020-10-14
- Last updated
- 2020-10-14
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04586361. Inclusion in this directory is not an endorsement.